Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dow Jones11-06

       income              4,925          884        12,069        2,168 
                      ----------    ---------    ----------    --------- 
Net loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) 
                      ==========    =========    ==========    ========= 
Net loss per share 
 attributable to 
 common 
 stockholders, 
 basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) 
                      ==========    =========    ==========    ========= 
Weighted average 
 common shares 
 outstanding, basic 
 and diluted          18,884,562    9,039,427    17,210,604    5,763,121 
                      ==========    =========    ==========    ========= 
 
Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact: 
Dan Ferry 
Life Science Advisors 
Daniel@lifesciadvisors.com 
617-430-7576

(END) Dow Jones Newswires

November 06, 2024 07:30 ET (12:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481603596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481603596","market":"other","top_or_hot":-1,"title":"Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n       income              4,925          884        12,069        2,168 \n                      ----------    ---------    ----------    --------- \nNet loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) \n                      ==========    =========    ==========    ========= \nNet loss per share \n attributable to \n common \n stockholders, \n basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) \n                      ==========    =========    ==========    ========= \nWeighted average \n common shares \n outstanding, basic \n and diluted          18,884,562    9,039,427    17,210,604    5,763,121 \n                      ==========    =========    ==========    ========= \n \nInvestor Contact: \nPraxis Precision Medicines \ninvestors@praxismedicines.com \n857-702-9452 \n \nMedia Contact: \nDan Ferry \nLife Science Advisors \nDaniel@lifesciadvisors.com \n617-430-7576 \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2024 07:30 ET (12:30 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>income              4,925          884        12,069        2,168 \n                      ----------    ---------    ----------    --------- \nNet loss             $   (51,910)  $  (24,632)  $  (124,140...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4097","symbol_name":"系统软件","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481603596","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481603596","pubTimestamp":1730896200,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor  confirmed for Q1 2025; NDA filing anticipated in 2025. Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies . Vormatrigine  on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025. Mr. Souza continued, \"Our ENERGY program for vormatrigine  is moving forward with strong interest, driven by insights from the ongoing observational EMPOWER study, and we are on track with our RADIANT and POWER1 trials. Additionally, we are actively exploring lifecycle expansion opportunities in Parkinson's Disease and pain. With strong financial and clinical positioning, we are set to build on this momentum, advancing all four clinical programs towards registrational readiness in 2025.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4097":"系统软件","BK4561":"索罗斯持仓","CNS":"科恩-斯蒂尔斯金融","BK4581":"高盛持仓","RPD":"Rapid7, Inc.","BK4135":"资产管理与托管银行","BK4183":"个人用品","BK4590":"PTP","BK4099":"汽车制造商","BK4200":"专卖店","ODD":"ODDITY Tech Ltd.","ASO":"Academy Sports & Outdoors, Inc.","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","MDCO":"麦迪逊医药","TM":"丰田汽车","BK4144":"石油与天然气的储存和运输","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4555":"新能源车","ET":"Energy Transfer LP","PRAX":"Praxis Precision Medicines, Inc.","BK4588":"碎股","03160":"华夏日股对冲"},"translate_title":"新闻稿：Praxis Precision Medicines提供公司最新动态并报告2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASO":1,"TM":1,"RPD":1,"PRAX":1,"ODD":1,"MDCO":1,"ET":1,"CNS":1,"03160":0.6},"content_text":"income              4,925          884        12,069        2,168 \n                      ----------    ---------    ----------    --------- \nNet loss             $   (51,910)  $  (24,632)  $  (124,140)  $  (96,399) \n                      ==========    =========    ==========    ========= \nNet loss per share \n attributable to \n common \n stockholders, \n basic and diluted   $     (2.75)  $    (2.72)  $     (7.21)  $   (16.73) \n                      ==========    =========    ==========    ========= \nWeighted average \n common shares \n outstanding, basic \n and diluted          18,884,562    9,039,427    17,210,604    5,763,121 \n                      ==========    =========    ==========    ========= \n \nInvestor Contact: \nPraxis Precision Medicines \ninvestors@praxismedicines.com \n857-702-9452 \n \nMedia Contact: \nDan Ferry \nLife Science Advisors \nDaniel@lifesciadvisors.com \n617-430-7576 \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2024 07:30 ET (12:30 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481603596"}